BioRestorative Therapies Files Q2 2025 8-K
Ticker: BRTX · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1505497
Sentiment: neutral
Topics: earnings, business-update, financials
Related Tickers: BRTX
TL;DR
BRTX dropped Q2 earnings & biz update 8-K. Check financials.
AI Summary
BioRestorative Therapies, Inc. filed an 8-K on August 12, 2025, to report on its Q2 2025 earnings and provide a business update. The filing includes financial statements and exhibits related to its operations. The company, formerly known as Stem Cell Assurance, Inc., is based in Melville, NY.
Why It Matters
This 8-K filing provides investors with crucial updates on BioRestorative Therapies' financial performance and business developments for the second quarter of 2025.
Risk Assessment
Risk Level: medium — The filing is a routine 8-K for earnings and business updates, but the company's specific financial health and operational progress will determine the actual risk.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Registrant
- August 12, 2025 (date) — Date of Report
- Q2 2025 (period) — Reporting Period
- Stem Cell Assurance, Inc. (company) — Former Company Name
- 40 Marcus Drive Melville, New York 11747 (address) — Principal Executive Offices
FAQ
What specific financial results were reported for Q2 2025?
The 8-K filing indicates that financial statements and exhibits related to Q2 2025 operations are included, but the specific numbers are not detailed in the provided text.
What business updates were provided by BioRestorative Therapies?
The filing states it is a business update for Q2 2025, but the specific details of the update are not elaborated in the provided text.
When was BioRestorative Therapies, Inc. formerly known as?
The company was formerly known as Stem Cell Assurance, Inc., with a name change date of November 10, 2010.
Where are BioRestorative Therapies, Inc.'s principal executive offices located?
The principal executive offices are located at 40 Marcus Drive, Melville, New York 11747.
What is the SEC file number for BioRestorative Therapies, Inc.?
The SEC file number for BioRestorative Therapies, Inc. is 001-37603.
Filing Stats: 721 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-08-12 16:16:41
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BRTX NASDAQ Capital Marke
Filing Documents
- brt81225.htm (8-K) — 26KB
- ex99_1.htm (EX-99.1) — 2KB
- pr_1.jpg (GRAPHIC) — 782KB
- pr_2.jpg (GRAPHIC) — 878KB
- pr_3.jpg (GRAPHIC) — 1232KB
- pr_4.jpg (GRAPHIC) — 161KB
- 0001021771-25-000113.txt ( ) — 4357KB
- brtx-20250812.xsd (EX-101.SCH) — 4KB
- brtx-20250812_lab.xml (EX-101.LAB) — 21KB
- brtx-20250812_pre.xml (EX-101.PRE) — 16KB
- brt81225_htm.xml (XML) — 4KB
02
Item 2.02. Result of Operations and Financial Condition. On August 12, 2025, BioRestorative Therapies, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2025 (the "Press Release"). The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the second quarter results. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information contained in the Press Release is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01
Item 7.01 Regulation FD Disclosure . See Item 2.02 above. The information in the Press Release is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Press Release will not be incorporated by reference into any registration statement filed by the Company under the Securities Act unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Current Report on Form 8-K with respect to the Press Release is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Press Release is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
Financial Statements and Exhibits
Financial Statements and Exhibits . (d) Exhibits . Number Description 99.1 Press release, dated August 12, 2025, issued by BioRestorative Therapies, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: August 12, 2025 By: /s/ Robert Kristal Robert Kristal Chief Financial Officer